About: Thibault Mazard

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thibault Mazard Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Mazard, Thibault (1980-...) Mazard, Thibault (1980-...) Mazard, Thibault (1980-...) Mazard, Thibault (1980-...)
Life Event	http://www.idref.fr/144613840/birth
preferred label	Mazard, Thibault (1980-...)
name	Thibault Mazard
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
isni:identifierValid	0000000120621419
Given name	Thibault
familyName	Mazard
has biographical i...tion (Deprecated)	Titulaire d'un doctorat d'exercice en médecine. Université de Montpellier 1. UFR de Médecine. Directeur de thèse (Montpellier, 2020)
gender	male
ORCID iD	0000-0002-5644-9603
Scopus ID	56693087400
is sameAs of	Mazard, Thibault (1980-...) Mazard, Thibault (1980-...) Mazard, Thibault (1980-...) Mazard, Thibault (1980-...)
is Thesis advisor of	http://www.sudoc.fr/258460016/id http://www.sudoc.fr/253603412/id
is Author of	http://www.sudoc.fr/144606852/id http://www.sudoc.fr/176951970/id http://www.sudoc.fr/153748524/id RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients Trajectoires de fatigue chez des patients suivis en chimiothérapie pour un cancer colorectal métastatique Machine Learning‐Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study https://hal.archives-ouvertes.fr/hal-03279637#id How patients with metastatic colorectal cancer do they cope with Cancer Related Fatigue (CRF): a longitudinal study about psychological factors Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care Cancer Related Fatigue (CRF) trajectories in metastatic colorectal cancer patients undergoing chemotherapy Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy Mechanical signatures of human colon cancers Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer https://hal.archives-ouvertes.fr/hal-02362679#id Blood contains circulating cell free respiratory competent mitochondria Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes Comment s’explique l’évolution différentielle de la fatigue chez des patients suivis en chimiothérapie pour un cancer colorectal métastatique ? Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) Le protocole FLOT est-il le nouveau standard de chimiothérapie péri-opératoire des cancers de l’estomac ? Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?] Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial Bone metastases in gastrointestinal cancer. Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1) Assessment of Dendrigrafts of Poly-L-Lysine Cytotoxicity and Cell Penetration in Cancer Cells
is primary topic of	http://www.idref.fr/144613840

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software